Hisamitsu Pharmaceutical Co., Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HTSUF research report →
Price Chart
About the company
Hisamitsu Pharmaceutical Co. , Inc. is a Japanese enterprise that develops and markets a range of pharmaceuticals, quasi-drugs, and medical devices.
- CEO
- Kazuhide Nakatomi
- IPO
- 2010
- Employees
- 2,759
- HQ
- Tosu, JP
Get TickerSpark's AI analysis on HTSUF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.04B
- P/E
- 22.44
- Fwd P/E
- 0.10
- PEG
- -2.49
- P/S
- 2.61
- P/B
- 1.46
- EV/EBITDA
- 11.06
- Div Yield
- 1.99%
- Gross Margin
- 58.96%
- Op Margin
- 10.99%
- Net Margin
- 11.75%
- ROE
- 6.99%
- ROIC
- 4.66%
Latest fiscal year · YoY change
- Revenue
- $163.49B+4.8%
- Gross Profit
- $96.40B+5.7%
- Op Income
- $17.97B
- Net Income
- $19.22B-11.7%
- EPS
- $269.27-8.9%
- OCF Growth
- -6.6%
- FCF Growth
- +90.5%
- 52W High
- $32.30
- 52W Low
- $28.94
- 50D MA
- $29.00
- 200D MA
- $29.00
- Beta
- 0.29
- RSI (14)
- 47
- Avg Volume
- 48
No earnings-call transcripts are available for HTSUF yet.
- Free Float
- 43.0%
- Shares Outstanding
- 70.40M
- Float Shares
- 30.26M
Our HTSUF coverage
Recent articles, reports, and earnings notes.
No research on HTSUF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HTSUF report →Hisamitsu Shares Surge as Company Confirms ¥457 Billion Management Buyout
gurufocus.com · Jan 7
Japan's Hisamitsu Pharmaceutical plans $2.55 billion MBO
reuters.com · Jan 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.